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T Alexander1, A Bondanza2, PA Muraro3, R Greco2, R Saccardi4, T Daikeler5, M Kazmi6, C Hawkey7, BP Simoes8, K Leblanc9, WE Fibbe10,
J Moore11,18, E Snarski12, T Martin13, F Hiepe1, A Velardi14,19, A Toubert15,19, JA Snowden16 and D Farge17 on behalf of the EBMT
Autoimmune Diseases Working Party (ADWP) and Immunobiology Working Party (IWP)
Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs).
Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by
haematopoietic SCT in chronic autoimmunity through eradication of the pathologic, immunologic memory and profound
reconﬁguration of the immune system, that is, immune ‘resetting’. Nevertheless, a number of areas remain unresolved and warrant
further investigation to reﬁne our understanding of the underlying mechanisms of action and to optimize clinical SCT protocols.
Due to the low number of patients transplanted in each centre, it is essential to adequately collect and analyse biological samples in
a larger cohort of patients under standardized conditions. The European society for blood and marrow transplantation
Autoimmune Diseases and Immunobiology Working Parties have, therefore, undertaken a joint initiative to develop and implement
guidelines for ‘good laboratory practice’ in relation to procurement, processing, storage and analysis of biological specimens for
immune reconstitution studies in AD patients before, during and after SCT. The aim of this document is to provide practical
recommendations for biobanking of samples and laboratory immune monitoring in patients with ADs undergoing SCT, both
for routine supportive care purposes and investigational studies.
Bone Marrow Transplantation advance online publication, 10 November 2014; doi:10.1038/bmt.2014.251
INTRODUCTION
Background
Autoimmune diseases (ADs) are a heterogeneous group of
diseases affecting 8–10% of the population. Therapeutic immu-
nosuppression and novel biological therapies can suppress or
attenuate the inﬂammatory process as long they are applied, but
cannot switch off the underlying mechanisms inducing therapy-
free remission, that is, cure. Although effective in most cases,
chronic immunosuppression is associated with the reduction in
quality-of-life, cumulative toxicity and increased risk of cardiovas-
cular disease, and represents a considerable socioeconomic
challenge. For patients with major organ involvement and
therapy-resistant disease, high-dose immunosuppression followed
by haematopoietic SCT has been used since 19951 worldwide and
was shown to induce treatment-free, long-term remissions in
several ADs.2–6 More recently, the use of MSCs has shown
promising results in chronic GVHD7 and ADs,8 and common
procedures for immune monitoring and biobanking will be
applied for these various types of SCT in AD patients.
The concept of SCT for ADs
On the basis of experimental data from animal models,9,10
haematopoietic SCT for ADs is applied with the goal of eradicating
the autoreactive immunologic memory and to regenerate a naive
and self-tolerant immune system from haematopoietic precursors.
It has remained unclear for a long time whether clinical remissions
observed after haematopoietic SCT were the result of prolonged
immunosuppression or the outcome of a true reconﬁguration of
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the immune system. A number of recent immunological studies
have provided the proof-of-concept that a chronic autoreactive
immune system can indeed be ‘reset’ into a naive and self-tolerant
immune system. These data include the regeneration of naive B
cells,5,11 thymic reactivation,5,12–14 the emergence of a polyclonal
TCR repertoire5,12,14 and restoration of Foxp3+ regulatory T-cell
(Treg) levels.15,16 Although interest in MSC usage was originally
raised by their potential capacity to differentiate into different cell
lineages, recent work showing their immunological properties has
led to a revized concept, envisioning their utilization for
immunomodulatory purposes. Their clinically relevant immuno-
modulatory potential has been demonstrated in clinical trials for
GVHD7 and in various types of ADs.8
Rationale for the development of guidelines for immune
monitoring and biobanking in AD patients after SCT
Early clinical guidelines and recommendations17 for SCT in ADs
were recently updated.18 Meanwhile, activity in the ﬁeld is
expanding with results from randomized phase II/III studies in
major disease indications, such as systemic sclerosis (ASTIS).2 In
parallel, clinical trials of MSC transplantation have been growing
in number.8 Although the mechanisms of action of SCT in ADs
have been partially elucidated, important issues remain un-
resolved from both clinical and scientiﬁc points of view. These
include the variability associated with type of AD, patient age,
continued use of immunosuppression and the effect of different
transplantation techniques, for example, variable conditioning
regimens and graft manipulation technology. The low number of
patients transplanted at each centre requires multicentre studies
under standardized conditions. The European Society for Blood
and Marrow Transplantation Autoimmune Diseases and Immuno-
biology Working Parties have, therefore, undertaken a combined
initiative to develop guidelines for harmonized ‘good laboratory
practice’ in biobanking and immune monitoring before and after
SCT in patients with ADs. These guidelines do not replace
established standard operating procedures in individual labora-
tories, and national regulatory requirements should always prevail.
However, they aim to support the establishment of an
international biobanking infrastructure and common testing
protocols, thereby facilitating collaborative and comparative
research studies in the ﬁeld of stem cell therapies for ADs.
GENERAL RECOMMENDATIONS
Clinical practice guidelines
In AD patients considered for SCT, referral should be made to a
centre with appropriate inter-disciplinary interaction between
haematological and AD specialists. Such centres should have
JACIE accreditation or equivalent18 and should provide pro-
grammes for long-term follow-up, quarterly for the ﬁrst year and
biannually follow-up consultation, thereafter, ideally with dual
review by both haematologists and disease specialists with
assessment of disease-speciﬁc activity scores. Where possible,
laboratories should participate in internal and external quality
assurance schemes for ﬂow cytometry, molecular genetics and
immunological markers. National and/or EU regulations should be
followed in relation to biobanking of cells and tissues.
Guidelines for basic laboratory immune analyses and biological
sample storage
A minimum set of laboratory analyses is recommended for
immune monitoring in patients before and at certain time-points
after SCT by all contributing centres (Table 1). These include full
blood count analysis on freshly isolated PBMCs, allowing
enumeration of CD4+ and CD8+ T cells, CD19+ B cells, CD3−/
CD56+ natural killer cells, CD3+/CD56+ natural killer-like T cells and
CD14+ monocytes. In addition, monitoring of total Ig levels and
analysis of serum autoantibody titres in Ab-mediated ADs are
recommended at baseline before the mobilization and SCT,
quarterly for the ﬁrst year and biannually thereafter. In addition to
the mentioned basic laboratory immune analyses, storage of
biological samples is recommended for extended immune
monitoring at later time-points. A list of biological samples
recommended for storage and potential immunologic investiga-
tions is provided (Table 2). To promote harmonized sample
handling across different sites, standardized protocols for sample
Table 1. Minimum requirements for immune monitoring before and after SCT in AD patients
Biological sample Recommended analyses Methods Time-point of analysis
Serum Total Ig levels (IgG, IgA, IgM) ELISA At baseline before the mobilization and SCT, at (3), 6,
(9), 12 months after SCT and biannually thereafter
Autoantibody titres
(in Ag-mediated ADs)
ELISA,
immunoﬂuorescence
PBMCs Expression analysis of CD45, CD3, CD4,
CD8, CD19, CD56 and CD14
Cytometry
Brackets indicate optional time-points for analysis.
Table 2. Recommendation for storage of biological samples and their potential exploitation for immunologic investigations before and after SCT in
AD patients
Biological sample Potential analyses Time-point of cryopreservation
Serum Proteomic proﬁling, cytokines, growth factors,
autoantibodies, circulating microRNAs
At baseline before the mobilization and SCT, at (3), 6, (9), 12 months
after SCT and biannually thereafter
PBMCs Cytometric proﬁling
DNA Genome-wide association studies, epigenetic analysis,
TRECs & KRECs
RNA Gene expression proﬁles, microRNA arrays At baseline before the mobilization and SCT and yearly after SCT
Abbreviations: KRECs=κ-deleting recombination excision circles; TRECs=T-cell receptor excision circles. Brackets indicate optional time-points for analysis.
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collection, processing and storage have been developed and are
provided in the Supplementary Appendix.
Expert centre recommendations for extended immune monitoring
For centres with expertize in ﬂow cytometry and adequate
immune monitoring core facilities, it is recommended to analyse a
broader set of biomarkers in patients before and after SCT. For
immunocytometric analysis, eight panels were deﬁned, dedicated
to ﬁne cytometric analyses of the different subsets of cells within
the major cellular populations (Table 3). Comparison between
centres may be possible given a preliminary calibration of all ﬂow
cytometers with the same rainbow ﬂuorescent particles. For
in-depth investigation of the T- and B-cell lymphopoiesis, it is
recommended to analyse T-cell receptor excision circles19 and
κ-deleting recombination excision circles,20 which can be
measured simultaneously using duplex real-time PCR.21,22 Further-
more, TCR repertoire analysis of peripheral blood T cells is
suggested with Vbeta analysis and ﬂow cytometry, spectratyping
or high-throughput sequencing.23 Providing that efﬁcient eradica-
tion of the autoreactive memory is a prerequisite for favourable
long-term responses, it is suggested to analyse the frequency of
autoantigen-speciﬁc T cells before and after SCT where possible,
for example, islet-Ag-speciﬁc T cells in type 1 diabetes.24 Here,
tetramer staining24,25 or magnetic pre-enrichment of CD154+
T cells provides techniques for high-resolution analysis of
Ag-reactive T cells directly from peripheral blood.26 In addition,
gene expression proﬁling of either whole blood or lymphocyte
subsets, using microarray technology, at deﬁned time-points
before and after SCT should be considered (Table 2).
Implications of immune monitoring for clinical practice:
recommendations for infection prophylaxis and re-vaccination
Current Autoimmune Diseases Working Party guidelines already
recommend that all patients receive Pneumocystis jiroveci, herpes
and antifungal prophylaxis and are monitored for CMV and EBV
(ideally by PCR) for infection (primary or reactivation) for at least
3 months after transplant, with active surveillance thereafter up to
2 years after SCT according to local practice.18 At that stage, CD4+
cell counts should be repeated and, if still below 200 cells/μL,
prophylaxis or quarterly monitoring should be continued. If the
patient suffers from recurrent or a life-threatening infection
despite neutrophil recovery and has Ig or Ig subclass deﬁciency,
i.v. Ig substitution should be considered after weighing up the
beneﬁts, risks and costs. Given the previous and often ongoing
administration of immunosuppressive drugs following SCT,
measurement of speciﬁc Ab levels is recommended before and
after re-vaccination when performed according to published
generic guidelines27 to conﬁrm protection and administer booster
vaccination in patients with inadequate response.
DISEASE-SPECIFIC RECOMMENDATIONS
Multiple sclerosis and neuromyelitis optica
Multiple sclerosis (MS) is the most common acquired demyelinat-
ing disease of the central nervous system. MS is the result of an
autoimmune inﬂammatory attack initiated by T and B cells and
directed against components of central nervous system myelin.
Axonal damage becomes prominent in secondary progressive
disease and is the main cause of irreversible disability. HLA genes
have a primary role in genetic susceptibility to MS, with a
predominant role from HLA-DRB1*15 in the majority of
populations.28,29 Recent GWAS identiﬁed multiple non-MHC loci
affecting the risk of developing MS.30 The majority of these genes
are immune related, for example, IL-2 and IL-7 receptors, CD6,
CD58, IRF8, and TNFRSF1A genes. The most commonly used rating
scale to grade neurological disability in patients with MS is the
Expanded Disability Status Scale.31 Historically considered a
variant of MS, neuromyelitis optica is recognized as a distinct
disease entity, whose hallmark is immune-mediated inﬂammation
of optic nerves and the spinal cord caused by autoantibodies to
the water channel aquaporin 4.32,33 Besides being pathogenic,
aquaporin 4 Abs are used as a marker of ‘minimal residual AD’
after SCT.34 In addition to the general guidelines and immune
monitoring panels described above, speciﬁc recommendations for
MS and neuromyelitis optica are provided (Table 4).
Systemic sclerosis
Systemic sclerosis (SSc) is a rare AD (prevalence 5–50 per 100 000)
characterized by early endothelial vascular damage with activation
of the immune response and enhanced collagen synthesis. Ag
stimulation and genetic susceptibility contribute to autoimmunity,
with consequent T- and B-cell activation, and ﬁbroblast activation
by pro-ﬁbrotic cytokines, that is, transforming growth factor-β and
connective tissue growth factor. Early T-cell inﬁltrates in skin and
pulmonary tissue, autoantibody production by plasma cells,
notably, anti-centromere and anti-topoisomerase-I and the pre-
sence of macrophages or altered endothelial cells promote
inﬂammation and ﬁbrosis. Several genetic associations have been
observed between HLA types and autoantibody proﬁles, and
genome-wide screening studies identiﬁed speciﬁc nucleotide
polymorphisms in relevant genes related to SSc.35 More recently,
use of microarray technology showed signiﬁcant differences of
gene patterns in skin biopsies from patients with diffuse and
limited SSc, which also differed from normal controls.36 In this
context, a few years ago, the EUSTAR biobanking group
Table 3. Panels for ﬂow cytometric analyses
Panel Analysis of markers Time-point of analysis
T-cell differentiation CD4, CD8, CD45RA, CD31, CCR7 CD28,
CD27, CD57
At baseline before the mobilization and SCT, at (3), 6, (9), 12 months
after SCT and yearly thereafter
T-cell receptor subsets and
activation
CD4, CD8, TCRab, TCRgd, CD69, CD38,
CD45RA, CD25
Regulatory T cells CD4, CD8, Foxp3, CD25, CD127,
CD45RA, Ki-67
B cells CD19, IgD, IgM, CD27, CD38, CD24
Plasma cells CD19, CD27, CD20, CD38, CD138,
HLA-DR
DCs CD45, CD11c, HLA-DR, BDCA-2, CD86
MSC CD45, CD34, CD80, CD86, CD73, CD90,
CD105, CD271
Master transcription factors CD3, CD4, T-bet, GATA-3, RORγt, Bcl-6
Brackets indicate optional time-points for analysis.
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developed guidelines for collection, storage and distribution of
SSc biospecimens (www.eustar.org). In addition to documenting a
minimal essential data set, acquisition and storage of blood
samples, and skin biopsies from patients with SSc after SCT are
strongly encouraged in expert centres (Table 4).
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a rare chronic AD
(prevalence 20–150 cases per 100 000) with heterogeneous
clinical manifestations.37 It is characterized by the generation of
Abs directed against a variety of autoantigens, including nuclear
and cytoplasmic Ags, and by complement activation.37 Auto-
reactive plasma cells are key players in the induction and
perturbation of immunopathology in SLE, and short-lived
(HLA-DRhigh) plasmablasts are readily detectable in the peripheral
blood of patients with active disease.38 Another hallmark of SLE is
the upregulation of IFN-regulated gene transcripts.39 IFNα and its
response proteins IP-10 and Siglec-1 are established markers for
monitoring disease activity in SLE.40 Circulating Foxp3+ Tregs are
expanded in SLE, with Helios-expressing Tregs being the most
prominent Treg subset, which correlates with disease activity.41
Disease activity is most commonly measured by SLE disease
activity index that comprises relevant clinical and laboratory
values.42 On the basis of these disease-speciﬁc features,
recommendations for immune monitoring in SLE are provided
(Table 4).
Crohn’s disease
Crohn’s disease is a chronic inﬂammatory bowel disease
characterized by recurring episodes of inﬂammation of the
gastrointestinal tract. It is thought to arise by dysregulated
mucosal immune responses to the gut ﬂora in genetically
susceptible individuals.43 GWAS and meta-analyses have identiﬁed
140 susceptibility loci to Crohn’s disease in Caucasians, but their
heritability is not fully explained.44 Disease activity is monitored by
symptom-based scores, most commonly the Harvey–Bradshaw
index45 and the Inﬂammatory Bowel Disease Questionnaire.46
Recent studies revealed an altered intestinal microbial and
peripheral blood T-cell phenotype, in particular involvement of
Th17 cells and IL-21/IL-22-producing CD4+ T cells in Crohn’s
disease.47,48 In addition, several biomarkers were shown to be
important in assessment of disease, most notably serum cytokines
(IL-22), metalloproteinase 9 and faecal calprotectin.49 In addition
to the general recommendations for immune monitoring, speciﬁc
parameters of the immune system may be important in Crohn’s
disease (Table 4).
Type 1 diabetes
Type 1 diabetes mellitus is an AD caused by autoreactive CD4+
and CD8+ T cells against insulin-producing islet cells.50 Although
the current standard treatment is insulin replacement therapy,
several clinical trials for haematopoietic SCT have demonstrated
long-term, insulin- and drug-free remissions in new-onset
type 1 diabetes mellitus.4,51 Following SCT, metabolic end points
such as C-peptide secretion, HbA1c level and daily insulin need
should be monitored. Immunological end points can give better
information on the efﬁcacy of the immune intervention. Although
no correlation with disease activity has been described between
several islet-speciﬁc Abs involved in type 1 diabetes mellitus
(ICA-512/IA-2, GAD65),50,52 their prognostic and predictive value in
the context of SCT remains to be determined. Monitoring T-cell
responses after SCT may be more relevant. Here, tetramer-staining
techniques allow testing T-cell responses to HLA-A2-restricted
insulin B10, pre-pro-insulin, islet Ag, GAD65 and pre-pro islet
amyloid polypeptide.24,25 We recommend also considering the
publication of the T-cell workshop initiative of the Immunology of
Diabetes Society regarding guidelines on how to handle biological
samples in clinical type 1 diabetes mellitus trials.53,54
Rheumatoid arthritis and juvenile idiopathic arthritis
Rheumatoid arthritis (RA), affecting ~ 1% of the population, is
characterized by chronic joint inﬂammation, autoantibody pro-
duction and variable degrees of bone and cartilage erosion.55
Disease activity can be measured using the Disease Activity Scores
and Clinical Disease Activity Index.56 Immunopathology includes
break of tolerance and accumulation of immune effector cells
including macrophages and osteoclasts, DCs, B and T cells,
especially Th17 subsets. Reduced T-cell receptor excision circles
and shortened telomeres result in a contracted TCR repertoire in
both naive and memory T cells.57,58 Haematopoietic SCT was
applied as a salvage therapy in severely affected patients in the
‘pre-biologic era’. Although remission occurred in the majority of
cases, recurrence was common, irrespective of CD34+ graft
selection.59,60 In JIA patients undergoing Auto-SCT, restoration of
initially reduced Foxp3+ Treg levels was observed with change in
autoreactive T cells from a pro-inﬂammatory (IFN-gamma and
T-bet high) to a tolerant phenotype (IL-10 and GATA-3 high) after
SCT.15 Disease-speciﬁc recommendations for immune monitoring
in RA/JIA are provided (Table 4).
CONCLUSIONS
Although activity in the ﬁeld of SCT for ADs is rapidly expanding,
the interpretation of results obtained from immune monitoring of
clinical trials is often limited due to the heterogeneity of methods
that are used for sample processing and analysis. With the
guidelines provided here, we aim to deﬁne ‘good laboratory
practice’ in handling of biological samples and to harmonize
methods for preparation, storage and analysis of biological
specimens for immune reconstitution studies. The implementation
and dissemination of these guidelines aim to support the
establishment of an international biobanking infrastructure and
common testing protocols. Adequate reporting and connection
between the individual centres exploiting these data will foster
collaborative and comparative research studies throughout
Europe for better patient care and to reﬁne our understanding
of the underlying mechanisms of action that may directly translate
into optimized protocols for SCT in ADs.
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